Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overactive Bladder Ads Become Frequent; 3 DTC Spots Break In Last 2 Months

Executive Summary

Pfizer, Johnson & Johnson and GlaxoSmithKline/ Yamanouchi have each released new direct-to-consumer TV advertisements for their overactive bladder products in the last two months as the sector has become more competitive

You may also be interested in...



Overactive Bladder Market New Entrants Are Targeting Specialty Physicians

Recent entrants to the overactive bladder category are focusing on capturing market share through specialty physicians, Indevus Exec VP and Chief Sales & Marketing Officer John Tucker said

Overactive Bladder Market New Entrants Are Targeting Specialty Physicians

Recent entrants to the overactive bladder category are focusing on capturing market share through specialty physicians, Indevus Exec VP and Chief Sales & Marketing Officer John Tucker said

GSK Launching Vesicare, Boniva Without Adding Reps; “Efficiency” Is Key

GlaxoSmithKline is launching Vesicare and Boniva without increasing the size of its sales force

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel